Navigation Links
'Activating' RNA takes DNA on a loop through time and space
Date:2/17/2013

Long segments of RNA encoded in our DNA but not translated into proteinare key to physically manipulating DNA in order to activate certain genes, say researchers at The Wistar Institute. These non-coding RNA-activators (ncRNA-a) have a crucial role in turning genes on and off during early embryonic development, researchers say, and have also been connected with diseases, including some cancers, in adults.

In an online article of the journal Nature, a team of scientists led by Wistar's Ramin Shiekhattar, Ph.D., detail the mechanism by which long non-coding RNA-activators promote gene expression. They show how these RNA molecules help proteins in the cell to create a loop of DNA in order to open up genes for transcription. Their experiments have also described how particular ncRNA-a molecules are related to FG syndrome, a genetic disease linked to severe neurological and physical deficits. "These ncRNA-activators can activate specific genes by working with large protein complexes, filling in a big piece of the puzzle," said Shiekhattar, Herbert Kean, M.D., Family Professor and senior author of the study. "Our DNA encodes thousands of these ncRNA-activators, each with a role in timing the expression of a specific gene. As we learn more about non-coding RNA, I believe we will have a profoundly better understanding of how our genes function."

Their findings also provide a plausible mechanism of how locations along chromosomes, classically known as "enhancer" elements, can influence the expression ("reading") of genes located 5,000 to 100,000 base pairs ("letters") of DNA away. According to their findings, ncRNA-a molecules bind to large protein complexes to form a loop of DNA, which then opens up the gene to the molecular machinery that transcribes DNA. "There is an abundance of evidence to indicate that enhancers are critical components of transcription during embryonic development and disease process," Shiekhattar said.

"Non-c
'/>"/>

Contact: Greg Lester
glester@wistar.org
215-898-3934
The Wistar Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. UC research takes a new approach to identifying food deserts
2. Building healthy bones takes guts
3. REACH news: European ombudsman takes up PETA complaint
4. Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player
5. It takes two to tangle: Wistar scientists further unravel telomere biology
6. NSF interdisciplinary program takes on critical national research priorities
7. University of Leicester takes delivery of unique eye imaging equipment
8. ONR-funded research takes flight in Popular Science article
9. Barley takes a leaf out of reindeers book in the land of the midnight sun
10. Why do people choke when the stakes are high?
11. Explosive breakthrough in research on molecular recognition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2014)... 6, 2014 - Insilico Medicine, Inc, a Baltimore-based ... age related diseases announced a research collaboration with ... Champions Oncology, Inc (OTC: CSBR). , "There are ... medicine, but Champions Oncology,s TumorGraft technology is unique ... chemotherapy regimen experimentally generating vast amounts of valuable ...
(Date:11/4/2014)... Nov. 5, 2014 – University of Utah engineers developed ... help jet fuel produce electricity without needing to ignite ... to power portable electronics, off-grid power and sensors. , ... in the American Chemical Society journal ACS Catalysis ... a chemical reaction between a fuel and an oxygen-rich ...
(Date:11/4/2014)... study examining only marketing directed at children on ... has found that the majority of black, middle-income ... marketing tactics. , Authored by Arizona State University ... is the first to examine the use of ... fast food restaurants and its relationship to demographics. ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Jet-fueled electricity at room temperature 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3
... alarming invasion of round goby into Great Lakes tributaries: ... A team of scientists from the University of Toronto, ... of Guelph has identified a drastic invasion of round ... of the Thames, Sydenham, Ausable and Grand Rivers. A ...
... awarded through federal stimulus research funding, a Kansas State ... eventually help diabetics preserve their eyesight. Dolores Takemoto, ... from the National Eye Institute to study how a ... protein kinase C gamma, called PKC gamma, and how ...
... , , , WALL, N.J., Aug. ... will be holding its second quarter conference call, which will be broadcast ... Eastern Time. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ) , ... International, Inc. Second Quarter 2009 Conference Call, When: ...
Cached Biology News:BIO-key(R) Announces Second Quarter Conference Call Schedule 2
(Date:11/26/2014)... and WILMINGTON, DE (PRWEB) November 26, 2014 ... Annual MPN Heroes recognition reception on December 5, 2014, ... Hematology’s annual meeting. The MPN Heroes event will honor ... in the field of myeloproliferative neoplasms (MPNs). , ... "Nashville," will discuss his family's cancer journey at the ...
(Date:11/26/2014)... -- Bio-Techne Corporation (NASDAQ: TECH ) announced ... to serve in a newly created position of Senior ... will be responsible for managing the operations of Bio-Techne,s ... acquired in July 2014 and the recently acquired CyVek ... -based ProteinSimple develops and commercializes proprietary systems and consumables ...
(Date:11/24/2014)... Nov. 24, 2014  IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has submitted ... U.S. Food and Drug Administration (FDA), which brings the ... seven, with eighteen submissions now pending at the FDA. ... CEO of the Company, commented, "Our team here at ...
(Date:11/24/2014)... NAMUR , Belgium , Nov. 24, ... life sciences company focused on developing diagnostic tests for cancer ... lung cancer study will be presented at the Science for ... Louvain-la-Neuve, Belgium . The data come from ... collected at the Pneumology department of the Centre Hospitalier Universitaire ...
Breaking Biology Technology:CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3IGI Laboratories, Inc. Announces ANDA Submission 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6
... Aug. 22 DNA2.0,Inc. (http://www.DNA20.com ), ... and,Operon Biotechnologies (http://www.operon.com ), a leader ... a partnership to utilize their,synergistic technologies and ... production platform with DNA2.0,s,gene synthesis process, the ...
... 21 ,Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... (SAR) of a class of,internally-developed compounds that ... the company as potential treatments for irritable ... is currently,under evaluation in a Phase 1b ...
... Under Fire, WORCESTER, Mass., Aug. 21 ... proud to announced that Dr.,Robert Lanza, the company,s ... recognized for his research and contributions to stem,cell ... PharmaVOICE (cover,story July/August issue). Dr. Lanza is one ...
Cached Biology Technology:Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 3Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 2Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 3
Human GATA-2 Affinity Purified Polyclonal Ab...
... microPET 120 utilizies CTI Molecular Imaging's proprietary ... same imaging volume as the R4. ... sensitivity of any commerically avaiable PET scanner. ... spatial resolution of any scinitallor based PETsystems. ...
... EVO series offers versatile liquid handling platforms ... a wide variety of life science applications.The ... base sizes (75, 100, 150 and 200 ... a platform that will advance with their ...
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
Biology Products: